33 Appendices CHAPTER 5 SUPPLEMENTARY METHODS In- and exclusion criteria Tumor patients Patients who had any prior cancer treatment (i.e. operation [except biopsy before resection], chemotherapy, radiotherapy) were not included in the retrospective cohort. Additional inclusion criteria for the current study were availability of preoperative neurocognitive assessment, fluent in Dutch and a pre-operative T2 FLAIR MRI with slice thickness ≤5 mm in order to maintain adequate quality for lesion segmentation. No criterion was set for the amount of completed neurocognitive tasks. The tumor location on the T2 FLAIR had to be representative of the tumor at the time of the neurocognitive assessment as visible on other imaging modalities as determined by the neurologist (TS). Glioma patients with a history of neurological or psychiatric disease potentially interfering with the current neurocognitive performance or imaging were excluded for the current study. Stroke patients Stroke patients were asked to participate if they were admitted to any of the following hospitals in the Netherlands between September 2015 and December 2019 in the Netherlands: Amsterdam University Medical Center (Amsterdam UMC), Radboud University Medical Center (Radboudumc) in Nijmegen, University Medical Center Groningen (UMCG), University Medical Center Utrecht (UMCU), Onze Lieve Vrouwe Gasthuis (OLVG), Maasziekenhuis Pantein, Rijnstate, Ommelander Ziekenhuis Groep, St. Antonius Ziekenhuis, and Diakonessenhuis. Patients were included for the current analyses if they were diagnosed with cerebral ischemic stroke made by a neurologist and fluent in Dutch. Exclusion criteria were 1) prior stroke based on imaging, 2) presence of another neurological, psychiatric or other diagnosis that may interfere with cognitive testing/imaging, 3) pre-existing cognitive decline (using a short informant-based questionnaire to asses change in cognitive functioning prior to stroke; cognitive decline was defined as a score >3.6 on the Dutch version of the Informant Questionnaire on Cognitive Decline in the Elderly [IQCODE]81). Neurocognitive assessment All subjects underwent a neurocognitive assessment that included measures of language, attention, executive functions, memory, visuoconstruction and psychomotor speed. The neurocognitive assessment was administered via the
RkJQdWJsaXNoZXIy MTk4NDMw